Jornal SBC 192 | Julho 2018

Expediente 4 Diretoria SBC Update On-line amplia a cobertura de notícias científicas 3 Diretoria Tribunal de Justiça decide por unanimidade a improcedência da ação que pedia a anulação da eleição de 2.016 16 Regionais Estaduais promovem ações para a população e eventos aos especialistas 18 Departamentos DA altera regulamento interno para se alinhar às normas da SBC 20 SBC na Mídia Diretriz da SBC é citada em Globo Repórter sobre coração 22 Histórias da Cardiologia Adrenalina pura 23 Cirurgia Cardíaca Aorta e Cirurgião Cardiovascular 24 Crônicas do Coração Caminhos do coração na literatura brasileira 25 Parceiros da Cardiologia Interfarma comunica mudança na presidência 26 Calendário 5 Diretoria Consulta Pública sobre carreira de médico de Estado continua aberta 6 Diretoria Melhor organização política para os médicos é defendida 8 SBC 2018 Congresso Brasileiro de Cardiologia tem mais de 1.500 trabalhos submetidos 9 Dia a Dia do Cardiologista: Gol da ciência brasileira aplicada ao futebol 11 Prevenção Prevenção cardiovascular dos trabalhadores é discutida pela Fiesp 12 Prevenção Campanha contra o tabaco é deflagrada em mídias sociais 13 Prevenção SBC e Regional organizam Tenda do Coração em Goiânia Invited editorial Cholesterol and inflammation: The lesser the better in atherothrombosis Viviane Z Rocha 1 and Raul D Santos 1,2 For decades, longitudinal studies have supported the multifactorial nature of atherosclerosis. Indeed, unless inexceptional cases,thereis nosinglecause thatis fun- damental or sufficient by itself for the development of atherosclerotic disease. Overall, a variable combination of the so-called risk factors initiates the atherosclerosis process,andmaycontributetoitsevolution,andultim- atelyto itscomplications. Interestingly, sincetheuseof themedicalterm‘‘riskfactor’’byKanneletal. 1 wholed the way for the widely recognized Framingham Heart Study, the list of potential risk factors for cardiovascu- lar disease has dramatically increased. In addition to traditional risk factors such as hypercholesterolemia, for which the pivotal influence on the development of coronary heart disease has been established since the 1960s, several different plasma ‘‘markers’’, causal or not, emerged several years ago with the promise to helpidentifying thosepersonswhoarepronetoprema- ture atherothrombosis. 2–4 Among the distinct bio- markers, those reflecting a low-grade inflammatory status gathered most of the attention of scientific com- munity, not only because of their power of prediction of cardiovascular events observed in large-scale epide- miologic studies (high-sensitivity C-reactive protein (hsCRP) being the best example), 2 but also due to a well-recognized role of inflammation in atherosclerosis from experimental studies in the last three decades. 5 In thisissueof EuropeanJournalofPreventiveCardiology , a Working Group of Atherosclerosis and Vascular Biology of the European Society of Cardiology addresses the close connections between these two risk factors, hypercholesterolemia and inflammation, concerning their synergistic biological contributions to atherosclerosis, and also their specific therapies, which nowseemcomplementaryapproachestoreducecardio- vascular risk (Table 1). 6 Cholesterol and inflammation – ‘‘partners in crime’’ As described in this Consensus paper, cholesterol and inflammation are biologically interrelated in their impact on atherosclerosis. 6 The entry and retention of low-density lipoprotein (LDL) particles within the arterial wall trigger several inflammatory signals, cul- minatingintheexpressionofadhesionmoleculesbythe endothelium and the local secretion of cytokines and chemokines, which ultimately contribute to accu- mulation of macrophages and other inflammatory cellsinthesubendothelialspace. 5,7 Thislipid-inflamma- tion interface reunites enough elements for setting up a proper soil for atherosclerosis initiation and often times, atherosclerosis progression. Beyond the well-known biological plausibility behind cholesterol’s role in atherogenesis, the causal relationship between low-density lipoprotein choles- terol (LDL-C) and atherosclerotic coronary heart dis- ease is currently unequivocal, with consistent and robust evidence from prospective epidemiologic cohort studies, 8 Mendelian randomization studies, 9,10 andrandomizedtrialsofdifferentLDL-loweringthera- pies 10–12 that act by enhancing the LDL receptor- mediated apolipoprotein B containing lipoprotein clearance pathway. Cumulative data, including over 20m person-years of follow-up, have supported a dose-dependent, log-linear association between the magnitude of exposure to LDL-C and risk of athero- sclerotic cardiovascular disease (ASCVD). 10 The recent studies of outcomes of a new class of potent LDL- C-lowering agents, the monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), reinforced this causal association. The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial, 13 the combined Studies of PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE) trials, 14 and the recently presented Evaluation of Cardiovascular Outcomes After an 1 LipidClinicHeartInstitute(InCor),UniversityofSaoPauloMedical SchoolHospital,Brazil 2 HospitalIsraelitaAlbertEinstein,Brazil Correspondingauthor: RaulDSantos,UnidadeClinicadeLipidesInCor-HCFMUSP,Av.DrEneas C.Aguiar44,Cep05403-900,SaoPaulo,SP,Brazil. Email :Raul.santos@incor.usp.br EuropeanJournalofPreventive Cardiology 0(00)1–4 ! TheEuropeanSocietyof Cardiology2018 Reprintsandpermissions: sagepub.co.uk/journalsPermissions.nav DOI:10.1177/2047487318772936 journals.sagepub.com/home/ejpc Taqui News Brasileiros assinam editorial de publicação da ESC 14 7 Diretoria Paciente cardiovascular 4.0 por Evandro Tinoco Mesquita Jornal SBC é o boletim informativo da Sociedade Brasileira de Cardiologia, uma publicação mensal. Presidente da SBC Oscar Pereira Dutra Diretor de Comunicação e Editor Romeu Sergio Meneghelo Coeditores Domingo Marcolino Braile, Protásio Lemos da Luz e Reinaldo Mattos Hadlich Redação Av. Marechal Câmara, 160/330 - Centro CEP: 20020-907 - Rio de Janeiro - RJ (21) 3478-2700 ou 0800 314 4409 jornalsbc@cardiol.br Departamento Comercial (11) 3411-5500 - comercial@cardiol.br Jornalista Responsável José Roberto Luchetti, Mtb 30.638 Ouvidoria 0800 314 4409 - ouvidoria@cardiol.br Produção Editorial e Edição de Textos SBC - Tecnologia da Informação e Comunicação - Núcleo Interno de Publicações Projeto Gráfico Oriente Comunicação Diagramação SBC - Tecnologia da Informação e Comunicação Núcleo Interno de Design Sociedade Brasileira de Cardiologia Av. Marechal Câmara, 160/330 - Centro CEP: 20020-907 - Rio de Janeiro - RJ (21) 3478-2700 ou 0800 314 4409 sbc@cardiol.br jornal.cardiol.br Os artigos assinados não refletem necessariamente a opinião do jornal. Filiada à Associação Médica Brasileira Relação Médico/ Paciente Paz na SBC, por Protásio Lemos da Cruz 23